CME Peer-to-Peer Dialogue features insightful audio commentary from a prestigious group of experts in diabetes management. Listen in for state-of-the-art information as they address timely, clinically relevant topics.

Ralph A. DeFronzo, MD (Chairperson) Professor of Medicine Chief of the Diabetes Division University of Texas Health Science Center Audie L. Murphy Memorial VA Hospital San Antonio, Texas

Patrick J. Boyle, MD Professor of Medicine Lead Physician, Diabetes Care Management Team University of New Mexico Albuquerque, New Mexico

Richard E. Pratley, MD Professor of Medicine Director, Diabetes and Metabolism Translational Medicine Unit University of Vermont College of Medicine Colchester Research Facility Colchester, Vermont

This educational activity is designed for physicians, doctors of osteopathy, family physicians, podiatric physicians, physician assistants, nurses, nurse practitioners, dietitians, pharmacists, psychologists, certified diabetes educators, and other health care professionals who care for patients with diabetes and who manage the complications related to this disease.

After participating in this educational curriculum, health care professionals should be able to:

• Assess the unique benefits and risks associated with newer antiglycemic therapies, including their use in combination with other classes of medication for glycemic control
• Describe the latest clinical trial results and unique clinical endpoints examining the effects of antiglycemic therapies on emerging strategies to get to A1C goals
• Define the effects of antiglycemic therapies on beta cell function and discuss why this may be an important consideration for the management and prevention of diabetes
  

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The France Foundation designates each podcast educational activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This activity is eligible for CME credit from March 2009 through March 31, 2010.

It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty involved in the development of this activity have disclosed any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a faculty member with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all faculty conflicts of interest prior to the release of this activity.

Patrick J. Boyle, MD, has served as a consultant for Takeda and has received honoraria from Amylin, Eli Lilly, and Takeda.

Ralph A. DeFronzo, MD, has received grants/research support from Amylin, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, and Takeda.

Richard E. Pratley, MD, has received grants/research support from Eli Lilly, GlaxoSmithKline, Mannkind, Merck,  Novartis, NovoNordisk, Pfizer, Roche, sanofi-aventis, and Takeda. He has served as a consultant for GlaxoSmithKline, Merck, Novartis, NovoNordisk, and Takeda. He owns stock in Novartis and has received honoraria from Merck, NovoNordisk, and Takeda.

This program is supported by an educational grant from Takeda Pharmaceuticals North America, Inc.

The France Foundation
230 Shore Road, Suite 202
Old Lyme, Connecticut 06371
Phone: 866-856-1998
Fax: 860-434-5390
E-mail: diabetes@francefoundation.com